PALO ALTO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of eflornithine to ...
PALO ALTO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of eflornithine to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback